INTRODUCTION
============

Vancomycin, is a glycopeptide antibiotic discovered during the middle of 19th century and is still considered as a first-line therapy for serious infections caused by methicillin resistance *Staphylococcus aureus* (MRSA).^[@B1],[@B2]^ Intensive care units are considered as the epicenters for nosocomial infections which are resistant to most of the antibiotics; hence, the use of systemic antibiotics including vancomycin is very high. Inappropriate use of systemic antibiotics increases antibiotic resistance, length of ICU stay, treatment cost, mortality, and morbidity rate.^[@B3]--[@B6]^

In India, the proportion of MRSA pathogen has increased from 29% in 2009 to 47% in 2014,^[@B7]^ and minimum inhibitory concentration (MIC) of vancomycin is also increasing.^[@B8],[@B9]^ This necessitates rational use of vancomycin. Pharmacokinetics--pharmacodynamics (PK--PD) assessment and therapeutic drug monitoring (TDM) of vancomycin have been recommended for better clinical outcome and dosing optimization. Various PK--PD studies have showed that 0--24 hours area under the curve (AUC) to MIC ratio of ≥400 is strongly associated with good clinical outcome. It is also recommended that the trough concentrations should always be maintained above 10 μg/mL to avoid development of resistance and for serious infections such as bacteremia, endocarditis, osteomyelitis, and meningitis and hospital-acquired pneumonia trough concentration should be 15--20 μg/mL.^[@B2],[@B10],[@B11]^

Despite being an old antibiotic, vancomycin pharmacokinetics (PK) data in critically ill patients are limited and there are no data in Indian population. During our recent observational study,^[@B12]^ we observed that vancomycin use is 23.23% in medical ICU without support of therapeutic drug monitoring services and evidence of pk data on vancomycin. Hence, present prospective single dose and steady state PK study was conducted in patients with suspected or proven gram-positive bacterial infections admitted to medical ICU.

MATERIALS AND METHODS
=====================

Study Design and Duration
-------------------------

This was a single center, single arm, prospective, single dose, and steady state PK study. Study was conducted over the period of 9 months from December 2015 to August 2016 in adult subjects admitted to medical ICU.

Study Sites
-----------

Department of Medicine and Clinical Pharmacology of a Tertiary Care Medical College and Hospital.

Ethics
------

Study was initiated after obtaining Institutional Ethics Committee approval. A written informed consent was obtained from all the subjects or legally acceptable representative before performing any study related activity. Study was prospectively registered with Clinical Trial Registry of India with registration number CTRI/2015/11/006393.

Study Participants
------------------

Subjects of either gender aged between 18 years and 65 years with suspected or proven gram-positive infection and requiring vancomycin (empirically or proven Gram positive bacterial infection) at the dose of 1 g every 12 hours were considered for the study. Subjects with creatinine clearance (CL~CR~) \<50 mL/minute,^[@B13]^ already receiving vancomycin therapy, hypersensitivity to vancomycin hydrochloride, or its excipients were excluded.

Study Procedure
---------------

Demographics (age, gender, and body weight), serum creatinine, Acute Physiology and Chronic Health Evaluation (APACHE) II score, Gram\'s stain and culture (for blood or any other appropriate body fluid specimen), antibiotic sensitivity, and MIC for vancomycin were performed prior to initiation of vancomycin therapy.

Vancomycin Treatment
--------------------

For the study purpose, vancomycin hydrochloride vials from the same batch which were available on hospital schedule (free of cost to the subject) were used throughout study period. Vancomycin at the dose of 1 g every 12 hours was administered via infusion pump over a period of 1 hour.

Blood Sampling
--------------

Blood samples (2 mL in a heparinized test tube) were collected from central line on day 1 (single dose) and day 3 (steady state, 48 hours) following the initiation of vancomycin hydrochloride injections, prior to dose administration (0 hour) and at 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours postdrug administration. Predose samples were also collected on days 2, 4, 5, 6, and 7. The plasma was separated and stored at −80°C for pending analysis.

Safety Assessment
-----------------

All adverse events (AEs)/serious adverse events (SAEs) with reference to below definitions were noted during entire the study duration.^[@B14]^

Adverse Event
-------------

Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

SAE or Serious Adverse Drug Reaction
------------------------------------

Any untoward medical occurrence that at any dose:

-   Results in death,

-   Is life-threatening,

-   Requires inpatient hospitalization or prolongation of existing hospitalization,

-   Results in persistent or significant disability/incapacity,

    or

-   Is a congenital anomaly/birth defect.

Estimation of Vancomycin by Liquid Chromatography-tandem Mass Spectrometry
--------------------------------------------------------------------------

A validated bioanalytical liquid chromatography mass spectrometry (LCMS) method for the estimation of vancomycin from plasma samples was used.^[@B15],[@B16]^ Vancomycin and internal standard (phenacetin) were extracted by solid-phase extraction technique using MCX 1 cc, 30 mg cartridges. Separation of components was performed on C18 column using acetonitrile:ammonium formate:formic acid (60:40:0.1%) as a mobile phase on ultra-fast liquid chromatography (Prominence, Shimadzu, Japan). Quantification was performed using the LCMS API 2000 (Applied Biosystems, MDX Sciex, Toronto, Canada) by multiple reaction monitoring transitions from 725 (diprotonated molecule with actual molecular weight 1449.265 g/mol) to 144.0 and 180.10 to 110.10 for vancomycin and internal standard, respectively. The spiked plasma drug concentrations were linear over the range of 0.259--100 μg/mL. The intraday and interday precision and accuracy was \<15% deviation.

Statistical Analysis
--------------------

No formal sample size calculation was done and a total of 15 subjects were enrolled. Pharmacokinetic parameters were derived by noncompartment modeling^[@B17]^ using Winnonlin (Version 6.3; Pharsight, St. Louis, MO). The trapezoidal approach was used to estimate AUC and clearance. The Matzke equation was used to estimate vancomycin clearance for each subject.^[@B18]^ Area under the curve was performed from 0 hour to 12 hours; hence, the AUC~0--24\ hours~ was calculated by doubling of AUC~0--12~.^[@B19]^

All statistical analysis was done on Statistical Package for the Social Sciences (SPSS) software version 20 (IBM, Armonk, NY, USA). Continuous numerical variables (such as CL~CR~, APACHE II score, and all pk parameters) and categorical variables (such as age, gender, and weight) were assessed for the normality using the Kolmogorov--Smirnov test. Normally distributed data were expressed as mean ± SD, and that not normally distributed was presented as median (range).

RESULTS
=======

Demographics
------------

A total of 15 subjects were enrolled (12 males and 3 females) with a median age of 30.00 years (18, 64) and a mean weight of 63.13 kg (±9.81). The mean APACHE II score and mean CL~CR~ was 10.00 (±6.75) and 87.30 mL/minute (±25.24), respectively. Single-dose PK was performed on 15 subjects and steady state PK was done in 12 subjects due to 2 deaths and a consent withdrawal prior to day 3. A total of 13 subjects received vancomycin for suspected gram-positive bacterial infection and 2 subjects received for proven methicillin-resistant coagulase-negative staphylococci (MRCoNS) infection with vancomycin MIC of 1.5 μg each. Demographics of each individual are presented in [Table 1](#T1){ref-type="table"}.

###### 

Demographics of participants in the study

  *Subject ID*   *Age (years)*                          *Sex*                     *Weight (kg)*   *APACHE II score*   *Creatinine clearance (mL/minute)*   *Clinical diagnosis*
  -------------- -------------------------------------- ------------------------- --------------- ------------------- ------------------------------------ ------------------------------------------
    1            25                                     Male                      65                0                 103.1                                Guillain--Barré syndrome
    2            18                                     Male                      59                6                   66.37                              Organophosphorus poisoning
    3            61                                     Male                      54              16                    59.25                              Guillain--Barré syndrome
    4            31                                     Male                      62              18                    84.47                              Tuberculous meningitis
    5            28                                     Male                      72              12                  100.8                                Herpes simplex encephalitis
    6            55                                     Male                      74              17                    96.02                              Guillain--Barré syndrome
    7            20                                     Male                      54              12                  100                                  Seizure disorder
    8            64                                     Male                      69              22                    94.68                              Intracranial bleed
    9            22                                     Male                      82                0                 161.26                               Left middle cerebral artery infarct
  10             34                                     Female                    58                9                   72.58                              Cerebral venous thrombosis
  11             30                                     Male                      56              14                    77.78                              Tetanus
  12             30                                     Female                    52                2                   61.39                              Organophosphorus poisoning
  13             23                                     Female                    48                8                   79.42                              Pulmonary thromboemboly
  14             59                                     Male                      68                4                   66.11                              Left-sided community acquired pneumonia
  15             56                                     Male                      74              10                    86.33                              Right-sided community acquired pneumonia
  Mean           37.06 (±16.72), median = 30 (18, 64)   Males = 12, females = 3   63.13 (±9.81)   10.00 (±6.75)       87.30 (±25.24)                       

Pharmacokinetic Parameters
--------------------------

A wide interindividual variability in pharmacokinetic parameters of single dose and steady state was observed. The elimination half-life (*t*~1/2~) increased almost two-fold at steady state and was statistically significant (*p* = 0.024). The mean maximum concentration (*C*~max~), *t*~1/2~, AUC from 0 hour to 12 hours (AUC~0--12\ hours~), volume of distribution (Vd), and clearance (CL) after single dose were 36.46 μg/mL (±14.87), 3.98 hours (±1.31), 113.51 μg/mL (±49.51), 52.01 L (±31.31), and 8.90 mL/minute (±3.29), respectively, and at steady state were 40.87 μg/mL (±19.29), 6.27 hours (±3.39), 147.94 μg/mL (±72.89), 56.39 L (±42.13), and 6.98 mL/minute (±4.48), respectively. The steady-state mean AUC from 0 hour to 24 hours (AUC~0--24\ hours~) was 295.89 μg/mL (±153.82) and only three subjects achieved AUC~0--24~ of \>400 μg at steady state. Individual pharmacokinetic parameters have been depicted in [Table 2](#T2){ref-type="table"} and mean concentrations following single dose and steady state at various time points are shown in [Figure 1](#F1){ref-type="fig"}.

A total of 45 trough levels were measured, of these 32 (71.11%) concentrations were below the recommended range of 10--20 μg/mL, 11 (24.44%) were within range, and 2 (4.45%) concentrations were above the recommended value. The details of trough concentrations are also presented in [Figure 2](#F2){ref-type="fig"}.

None of the study subject experienced any AE related to vancomycin dosing and infusion. However, three subjects died where the causes of death were type II respiratory failure, ventricular tachycardia with autonomic dysfunction in case of tetanus septic shock, and septicemia in a clinical case of pulmonary thromboembolism during postnatal care, respectively. One subject denied to give blood samples post day 2 of study drug administration; hence, this subject was withdrawn from the steady-state pharmacokinetic assessment.

###### 

Summary of single-dose and steady-state pharmacokinetic parameters

  *Pharmacokinetic parameter*       *Single-dose PK value*   *Steady-state PK value*
  --------------------------------- ------------------------ -------------------------
  *C*~max~ (μg/mL)                  36.47 (±14.87)           40.87 (±19.29)
  *C*~min~ (μg/mL)                  3.99 (±3.07)             5.46(±3.84)
  *T*~max~ (hour)                   1.02 (±0.06)             1.04 (±0.14)
  *T*~1/2~ (hour)                   3.98 (±1.31)             6.27 (±3.39)
  AUC~0--12~ (μg/mL)                113.52 (±49.19)          147.94 (±72.89)
  AUC~0--∞~ (μg/mL)                 129.49 (±54.73)          206.58 (±132.12)
  Vd (L)                            52.01 (±31.31)           56.39 (±42.13)
  CL (mL/minute)                    8.90 (±3.29)             6.98 (±4.48)
  Steady state AUC~0--24~ (μg/mL)   NA                       295.89 (±153.82)
  AUC~0--24/MIC~ (MRCoNS)           NA                       193.82 (±125.79)

PK, pharmacokinetics; *C*~max~, maximum concentration; *C*~min~, minimum concentration; *T*~max~, maximum time; *T*~1/2~, elimination half-life; AUC~0--12~, area under concentration--time curve from 0 hour to 12 hours; AUC~0--∞~, area under concentration--time curve from 0 to ∞; Vd, volume of distribution; CL, clearance; steady state AUC~0--24~, steady-state area under concentration--time curve from 0 hour to 24 hours; AUC~0--24/MIC~, area under concentration--time curve from 0 hour to 24 hours/minimum inhibitory concentration; MRCoNS, methicillin-resistant coagulase-negative staphylococci

DISCUSSION
==========

Understanding the pharmacokinetic and pharmacodynamic properties of antibiotics in critically ill patients is important due to different pathophysiologies. Vancomycin is being used since its discovery; however, PK--PD data in critically ill patients are limited. To our knowledge, this is a first Indian study conducted in critically ill subjects to assess the single dose and steady-state PK of vancomycin and a wide interindividual variability was observed in pharmacokinetic parameters in this population. The recommended dose (1 g every 12 hours) infused over 1 hour was well-tolerated by all subjects compared to the short duration of vancomycin which is known to be associated with many AEs.^[@B10],[@B20]^
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The *C*~max~ achieved at single dose and steady state in our study is comparable with those reported in ill patients and lower than those reported in healthy volunteers.^[@B21]--[@B23]^ The minimum concentration (*C*~min~) at single dose (3.99 μg/mL ±3.07) and steady state (5.46 μg/mL ±3.84) after administration of 1 g of vancomycin every 12 hours in ill subjects is comparatively lower than the healthy volunteers (7.9 μg/mL ±1.7 at steady state).^[@B21]^ In present study, at steady state, volume of distribution increased by 7.76% (from 52.01 L to 56.39 L), clearance decreased by 21.57% (from 8.90 mL/minute to 6.98 mL/minute), and half-life (*t*~1/2~) increased almost two-fold, i.e., from 3.98 hours (±1.31) to 6.27 hours (±3.39) with stable CL~CR~; however, these are statistically insignificant (except half-life). Our findings are in-line to the study of Polard et al.; however, they observed significant increase in (around 30%) steady-state volume of distribution, decrease in (around 30%) steady state clearance of vancomycin and two-fold increase in half-life.^[@B22]^ The increase in the vancomycin volume of distribution in ICU patients could be because of increased volume of extracellular fluids caused by microvascular damage and tissue edema induced by sepsis.^[@B22],[@B24]--[@B26]^ However, vancomycin is not highly protein bound (binding is around 50%); hence, it is unlikely that protein variability would affect its extravascular binding.^[@B27],[@B28]^ It was also advocated that the homeostatic response to acute cardiovascular failure may also increase the vancomycin distribution because of fluid retention; however, this association could not be evaluated in our study, since none of the enrolled subjects had any cardiovascular event.^[@B27]^ It has been stated that the decrease in clearance at steady state may because of decrease in extrarenal (metabolic or biliary excretion) clearance of vancomycin and/or a modification in renal tubular secretion or reabsorption; however, there is lack of direct evidence reported in humans.^[@B22],[@B29]^ Single-dose and steady-state half-lives achieved in our study are almost similar to the study conducted by Polard et al. with similar study population. These findings are also comparable with patients with normal renal function and shorter than patients with renal impairment.^[@B22],[@B30]^

It has been recommended that the AUC~0--24~/MIC ratio of ≥400 should be achieved for good clinical outcome.^[@B10],[@B11],[@B31]^ In present study, two subjects with MRCoNS achieved low AUC~0--24~/MIC ratio of 282.76 and 104.87 with an MIC of 1.5 μg and only 3 subjects achieved AUC~0--24~ of ≥400.

Peak concentrations of vancomycin have little importance, since bactericidal activity of vancomycin is independent of peak serum concentration. Also, calculating AUC/MIC is cumbersome since it involves serial vancomycin concentrations; therefore, trough concentrations are recommended as a surrogate marker.^[@B10]^ It was observed that the around 70% concentrations were below recommendations and only 25% achieved in targeted range with current vancomycin dosing. Similar study in ill patients conducted by Dedkaew et al. and Shahrami et al. also found that the ≥50% patients had subtherapeutic vancomycin concentrations.^[@B23],[@B32]^ Hence, individualization of vancomycin dosing is imperative to achieve good clinical outcome and to avoid resistance. It is also recommended that the vancomycin administration frequency may increase to determine the maintenance dose and dosing interval in critically ill patients with similar degree of renal function.^[@B23]^

Limitations
-----------

Present study conducted in only normal renal function population; therefore, pharmacokinetic findings of this study may not be applicable to patients with renal impairment.

CONCLUSION
==========

Wide interindividual variability was observed in pharmacokinetic parameters between ill patients, and changes in clearance, half-life, and volume of distribution over the course of vancomycin therapy were also seen. Recommended AUC~0--24hours~ and trough concentrations were not achievable in majority of patients with current vancomycin dosing at 1 g every 12 hours. Therefore, individual vancomycin dosing based on close monitoring of vancomycin serum concentrations is suggested in critically ill patients.
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